Free Access
Med Sci (Paris)
Volume 30, Number 8-9, Août–Septembre 2014
Page(s) 772 - 778
Section M/S Revues
Published online 01 September 2014
  1. Theuerkorn M, Fischer G, Schiene-Fischer C. Prolyl cis/trans isomerase signalling pathways in cancer. Curr Opin Pharmacol 2011 ; 11 : 281–287. [CrossRef] [PubMed] [Google Scholar]
  2. Lu KP, Hanes SD, Hunter T. A human peptidyl-prolyl isomerase essential for regulation of mitosis. Nature 1996 ; 380 : 544–547. [CrossRef] [PubMed] [Google Scholar]
  3. Liou YC, Ryo A, Huang HK, et al. Loss of Pin1 function in the mouse causes phenotypes resembling cyclin D1-null phenotypes. Proc Natl Acad Sci USA 2002 ; 99 : 1335–1340. [CrossRef] [Google Scholar]
  4. Ranganathan R, Lu KP, Hunter T, Noel JP. Structural and functional analysis of the mitotic rotamase Pin1 suggests substrate recognition is phosphorylation dependent. Cell 1997 ; 89 : 875–886. [CrossRef] [PubMed] [Google Scholar]
  5. Lu PJ, Zhou XZ, Shen M, Lu KP. Function of WW domains as phosphoserine- or phosphothreonine-binding modules. Science 1999 ; 283 : 1325–1328. [CrossRef] [PubMed] [Google Scholar]
  6. Yaffe MB, Schutkowski M, Shen M, et al. Sequence-specific and phosphorylation-dependent proline isomerization: a potential mitotic regulatory mechanism. Science 1997 ; 278 : 1957–1960. [CrossRef] [PubMed] [Google Scholar]
  7. Liou YC, Zhou XZ, Lu KP. Prolyl isomerase Pin1 as a molecular switch to determine the fate of phosphoproteins. Trends Biochem Sci 2011 ; 36 : 501–514. [CrossRef] [PubMed] [Google Scholar]
  8. Fujimori F, Takahashi K, Uchida C, Uchida T. Mice lacking Pin1 develop normally, but are defective in entering cell cycle from G0 arrest. Biochem Biophys Res Commun 1999 ; 265 : 658–663. [CrossRef] [PubMed] [Google Scholar]
  9. Wulf GM, Ryo A, Wulf GG, et al. Pin1 is overexpressed in breast cancer and cooperates with Ras signaling in increasing the transcriptional activity of c-Jun towards cyclin D1. EMBO J 2001 ; 20 : 3459–3472. [CrossRef] [PubMed] [Google Scholar]
  10. Rizzolio F, Lucchetti C, Caligiuri I, et al. Retinoblastoma tumor-suppressor protein phosphorylation and inactivation depend on direct interaction with Pin1. Cell Death Differ 2012 ; 19 : 1152–1161. [CrossRef] [PubMed] [Google Scholar]
  11. Van der Horst A, Khanna KK. The peptidyl-prolyl isomerase pin1 regulates cytokinesis through Cep55. Cancer Res 2009 ; 69 : 6651–6659. [CrossRef] [PubMed] [Google Scholar]
  12. Ryo A, Suizu F, Yoshida Y, et al. Regulation of NF-κB signaling by Pin1-dependent prolyl isomerization and ubiquitin-mediated proteolysis of p65/RelA. Mol Cell 2003 ; 12 : 1413–1426. [CrossRef] [PubMed] [Google Scholar]
  13. Yeh E, Cunningham M, Arnold H, et al. A signalling pathway controlling c-Myc degradation that impacts oncogenic transformation of human cells. Nat Cell Biol 2004 ; 6 : 308–318. [CrossRef] [PubMed] [Google Scholar]
  14. Farrell AS, Pelz C, Wang X, et al. Pin1 regulates the dynamics of c-Myc DNA binding to facilitate target gene regulation and oncogenesis. Mol Cell Biol 2013 ; 33 : 2930–2949. [CrossRef] [PubMed] [Google Scholar]
  15. Zheng Y, Xia Y, Hawke D, et al. FAK phosphorylation by ERK primes Ras-induced tyrosine dephosphorylation of FAK mediated by PIN1 and PTP-PEST. Mol Cell 2009 ; 35 : 11–25. [CrossRef] [PubMed] [Google Scholar]
  16. Zheng Y, Yang W, Xia Y, et al. Ras-induced and extracellular signal-regulated kinase 1 and 2 phosphorylation-dependent isomerization of protein tyrosine phosphatase (PTP)-PEST by PIN1 promotes FAK dephosphorylation by PTP-PEST. Mol Cell Biol 2011 ; 31 : 4258–4269. [CrossRef] [PubMed] [Google Scholar]
  17. Nishi M, Akutsu H, Masui S, et al. A distinct role for Pin1 in the induction and maintenance of pluripotency. J Biol Chem 2011 ; 286 : 11593–11603. [CrossRef] [PubMed] [Google Scholar]
  18. Rustighi A, Zannini A, Tiberi L, et al. Prolyl-isomerase Pin1 controls normal and cancer stem cells of the breast. EMBO Mol Med 2014 ; 6 : 99–119. [CrossRef] [PubMed] [Google Scholar]
  19. Matsuura I, Chiang KN, Lai CY, et al. Pin1 promotes transforming growth factor-β-induced migration and invasion. J Biol Chem 2010 ; 285 : 1754–1764. [CrossRef] [PubMed] [Google Scholar]
  20. Ryo A, Uemura H, Ishiguro H, et al. Stable suppression of tumorigenicity by Pin1-targeted RNA interference in prostate cancer. Clin Cancer Res 2005 ; 11 : 7523–7531. [CrossRef] [PubMed] [Google Scholar]
  21. Khanal P, Kim G, Yun HJ, et al. The prolyl isomerase Pin1 interacts with and downregulates the activity of AMPK leading to induction of tumorigenicity of hepatocarcinoma cells. Mol Carcinog 2012 ; 52 : 813–23. [PubMed] [Google Scholar]
  22. Jin H, Jiang J, Sun L, et al. The prolyl isomerase Pin1 is overexpressed in human esophageal cancer. Oncol Lett 2011 ; 2 : 1191–1196. [PubMed] [Google Scholar]
  23. Bao L, Kimzey A, Sauter G, et al. Prevalent overexpression of prolyl isomerase Pin1 in human cancers. Am J Pathol 2004 ; 164 : 1727–1737. [CrossRef] [PubMed] [Google Scholar]
  24. Ryo ALiou YC, Wulf G, Nakamura M, et al. PIN1 is an E2F target gene essential for Neu/Ras-induced transformation of mammary epithelial cells. Mol Cell Biol 2002 ; 22 : 5281–5295. [CrossRef] [PubMed] [Google Scholar]
  25. Ryo A, Liou YC, Wulf G, Lu KP. Prolyl isomerase Pin1: a catalyst for oncogenesis and a potential therapeutic target in cancer. J Cell Sci 2003 ; 116 : 773–783. [CrossRef] [PubMed] [Google Scholar]
  26. Smet-Nocca C, Launay H, Wieruszeski JM, et al. Unraveling a phosphorylation event in a folded protein by NMR spectroscopy: phosphorylation of the Pin1 WW domain by PKA. J Biomol NMR 2013 ; 55 : 323–337. [CrossRef] [PubMed] [Google Scholar]
  27. Kim G, Khanal P, Kim JY, et al. COT phosphorylates prolyl-isomerase Pin1 to promote tumorigenesis in breast cancer. Mol Carcinog 2013 ; doi: 10.1002/mc.22112. [Google Scholar]
  28. Lee TH, Chen CH, Suizu F, et al. Death-associated protein kinase 1 phosphorylates Pin1 and inhibits its prolyl isomerase activity and cellular function. Mol Cell 2011 ; 42 : 147–159. [CrossRef] [PubMed] [Google Scholar]
  29. Eckerdt F, Yuan J, Saxena K, et al. Polo-like Kinase 1-mediated phosphorylation stabilizes Pin1 by inhibiting its ubiquitination in human cells. J Biol Chem 2005 ; 280 : 36575–36583. [CrossRef] [PubMed] [Google Scholar]
  30. Teng BL, Hacker KE, Chen S, et al. Tumor suppressive activity of prolyl isomerase Pin1 in renal cell carcinoma. Mol Oncol 2011 ; 5 : 465–474. [CrossRef] [PubMed] [Google Scholar]
  31. Hennig L, Christner C, Kipping M, et al. Selective inactivation of parvulin-like peptidyl-prolyl cis/trans isomerases by juglone. Biochemistry 1998 ; 37 : 5953–5960. [CrossRef] [PubMed] [Google Scholar]
  32. Tatara Y, Lin YC, Bamba Y, et al. Dipentamethylene thiuram monosulfide is a novel inhibitor of Pin1. Biochem Biophys Res Commun 2009 ; 384 : 394–398. [CrossRef] [PubMed] [Google Scholar]
  33. Lee J, Kim S.. Current implications of cyclophilins in human cancers. J Exp Clin Cancer Res 2010 ; 29 : 97. [CrossRef] [PubMed] [Google Scholar]
  34. Yao YL, Liang YC, Huang HH, Yang WM. FKBPs in chromatin modification and cancer. Curr Opin Pharmacol 2011 ; 11 : 301–307. [CrossRef] [PubMed] [Google Scholar]
  35. Jordens J, Janssens V, Longin S, et al. The protein phosphatase 2A phosphatase activator is a novel peptidyl-prolyl cis/trans-isomerase. J Biol Chem 2006 ; 281 : 6349–6357. [CrossRef] [PubMed] [Google Scholar]
  36. Lavoie SB, Albert AL, Michel V. Pin1 : une peptidyl-prolyl cis/trans isomérase aux rôles insoupçonnés. Med Sci (Paris) 2003 ; 19 : 1251–1258. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  37. Bidard FC, Poupon MF. Biologie du processus métastatique. Med Sci (Paris) 2012 ; 28 : 89–95. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.